PARAMETERS OF LIPID METABOLISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND THYROID DYSFUNCTION

BACKGROUND. In CKD lipid metabolism disorders are associated with a high incidence of adverse outcomes. Dyslipidemia in patients with CKD is characterized by a decrease in HDL cholesterol, high triglyceride levels, and normal total cholesterol and LDL cholesterol levels. In CKD, a decrease in the functional activity of the thyroid gland (subclinical hypothyroidism) is often detected. THE AIM: to study the parameters of the lipid spectrum of blood in patients with different stages of chronic kidney disease and thyroid dysfunction. PATIENTS AND METHODS. A one-stage cross-sectional study of 457 patients with glomerulopathies without clinically significant diseases of the cardiovascular system with preserved ejection fraction (> 55% according to Simpson method) according to echocardiography was carried out. To identify thyroid dysfunction, a screening determination of the level of TSH, free T4 was assessed. The parameters of the blood lipid spectrum and GFR were assessed in all patients. Parametric and nonparametric methods of statistical analysis were used. RESULTS. Advanced stages of CKD are characterized by the formation of atherogenic dyslipidemias. 13.1% of patients received statin therapy, the target values of the blood lipid spectrum on statin therapy were not achieved. In the group of patients with nephrotic syndrome, the parameters of the blood lipid spectrum were significantly worse. Most of the patients with CKD were outside the target values of the blood lipid spectrum. In patients with TSH> 7.0 mIU / L, the content of TC, LDL, non-HDL was significantly higher than in the group of patients with normal thyroid function. CONCLUSION. Subclinical hypothyroidism contributes to the formation of atherogenic dyslipidemias in patients with CKD.

1. Khatiwada S, Rajendra KC, Gautam S et al. Thyroid dysfunction and dyslipidemia in chronic kidney disease patients. BMC Endocr Disord 2015;15:65. doi:10.1186/s12902-015-0063-9

2. Cappola AR, Desai AS, Medici M et al. Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment. Thyroid 2019;29(6):760–777. doi:10.1089/thy.2018.0416

3. Mikolasevic I, Žutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis 2017;10:35–45. doi:10.2147/IJNRD.S101808

4. Duntas L, Brenta G. Thyroid hormones: a potential ally to LDL-cholesterol-lowering agents. Hormones (Athens) 2016;15(4):500–510. doi:10.14310/horm.2002.1707

5. Smirnov AV, Shilov EM, Dobronravov VA et al. national guidelines. Chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment approaches. Nephrology (Saint-Petersburg). 2012;16(1):89–115 (In Russ.) doi:10.24884/1561-6274-2012-16-1-89-115

6. Duntas L, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am 2012;96(2):269–281. doi:10.1016/j.mcna.2012.01.012

7. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney. Kidney International Supplements 2013;3, 259–305. doi:10.1038/kisup.2013.42

8. Volkova AR, Dygun OD, Lukichev BG et al. Thyroid dysfunction in patients with chronic kidney disease: the state of the problem and the ways of solving. Nephrology (Saint-Petersburg). 2018;22(4):40–49 (In Russ.)

9. Parmar JA, Joshi AG, Chakrabarti M. Dyslipidemia and chronic kidney disease. ISRJ 2014;3:396–397

10. Fadeev VV. Clinical Practice Guidelines for Hypothyroidism in Adults: Co-sponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Clinical and experimental thyroidology 2012;8(3):9–16 (In Russ.) doi:10.4158/EP12280.GL

11. Duntas L, Brenta G. A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism. Front Endocrinol (Lausanne) 2018;9:511. doi:10.3389/fendo.2018.00511

12. Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment Nat Rev Nephrol 2018;14(1):57–70. doi:10.1038/nrneph.2017.155

13. Catapano AL, Graham I, De Backer G at al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Russian Journal of Cardiology 2017;5:7–77 (In Russ.)

14. Floriani C, Gencer B, Collet T-H, Rodondi N. Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. Eur Heart J 2018;39(7):503–507. doi:10.1093/eurheartj/ehx050